720 related articles for article (PubMed ID: 25798620)
1. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
Tanaka K; Sasayama T; Irino Y; Takata K; Nagashima H; Satoh N; Kyotani K; Mizowaki T; Imahori T; Ejima Y; Masui K; Gini B; Yang H; Hosoda K; Sasaki R; Mischel PS; Kohmura E
J Clin Invest; 2015 Apr; 125(4):1591-602. PubMed ID: 25798620
[TBL] [Abstract][Full Text] [Related]
2. Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma.
Wei W; Shin YS; Xue M; Matsutani T; Masui K; Yang H; Ikegami S; Gu Y; Herrmann K; Johnson D; Ding X; Hwang K; Kim J; Zhou J; Su Y; Li X; Bonetti B; Chopra R; James CD; Cavenee WK; Cloughesy TF; Mischel PS; Heath JR; Gini B
Cancer Cell; 2016 Apr; 29(4):563-573. PubMed ID: 27070703
[TBL] [Abstract][Full Text] [Related]
3. mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells.
Pusapati RV; Daemen A; Wilson C; Sandoval W; Gao M; Haley B; Baudy AR; Hatzivassiliou G; Evangelista M; Settleman J
Cancer Cell; 2016 Apr; 29(4):548-562. PubMed ID: 27052953
[TBL] [Abstract][Full Text] [Related]
4. Cooperative Blockade of PKCα and JAK2 Drives Apoptosis in Glioblastoma.
Wong RA; Luo X; Lu M; An Z; Haas-Kogan DA; Phillips JJ; Shokat KM; Weiss WA; Fan QW
Cancer Res; 2020 Feb; 80(4):709-718. PubMed ID: 31806641
[TBL] [Abstract][Full Text] [Related]
5. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
[TBL] [Abstract][Full Text] [Related]
6. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of SAPK2/p38 enhances sensitivity to mTORC1 inhibition by blocking IRES-mediated translation initiation in glioblastoma.
Cloninger C; Bernath A; Bashir T; Holmes B; Artinian N; Ruegg T; Anderson L; Masri J; Lichtenstein A; Gera J
Mol Cancer Ther; 2011 Dec; 10(12):2244-56. PubMed ID: 21911485
[TBL] [Abstract][Full Text] [Related]
10. Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.
Olmez I; Brenneman B; Xiao A; Serbulea V; Benamar M; Zhang Y; Manigat L; Abbas T; Lee J; Nakano I; Godlewski J; Bronisz A; Abounader R; Leitinger N; Purow B
Clin Cancer Res; 2017 Nov; 23(22):6958-6968. PubMed ID: 28814434
[No Abstract] [Full Text] [Related]
11. Suppression of the invasive potential of Glioblastoma cells by mTOR inhibitors involves modulation of NFκB and PKC-α signaling.
Chandrika G; Natesh K; Ranade D; Chugh A; Shastry P
Sci Rep; 2016 Mar; 6():22455. PubMed ID: 26940200
[TBL] [Abstract][Full Text] [Related]
12. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.
Lampa M; Arlt H; He T; Ospina B; Reeves J; Zhang B; Murtie J; Deng G; Barberis C; Hoffmann D; Cheng H; Pollard J; Winter C; Richon V; Garcia-Escheverria C; Adrian F; Wiederschain D; Srinivasan L
PLoS One; 2017; 12(9):e0185092. PubMed ID: 28950000
[TBL] [Abstract][Full Text] [Related]
13. MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.
Wu S; Wang S; Zheng S; Verhaak R; Koul D; Yung WK
Mol Cancer Ther; 2016 Jul; 15(7):1656-68. PubMed ID: 27196759
[TBL] [Abstract][Full Text] [Related]
14. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
[TBL] [Abstract][Full Text] [Related]
15. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
16. Brain Tumor Stem Cell Dependence on Glutaminase Reveals a Metabolic Vulnerability through the Amino Acid Deprivation Response Pathway.
Restall IJ; Cseh O; Richards LM; Pugh TJ; Luchman HA; Weiss S
Cancer Res; 2020 Dec; 80(24):5478-5490. PubMed ID: 33106333
[TBL] [Abstract][Full Text] [Related]
17. Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma.
Cruickshanks N; Zhang Y; Hine S; Gibert M; Yuan F; Oxford M; Grello C; Pahuski M; Dube C; Guessous F; Wang B; Deveau C; Saoud K; Gallagher I; Wulfkuhle J; Schiff D; Phan S; Petricoin E; Abounader R
Clin Cancer Res; 2019 Jan; 25(2):663-673. PubMed ID: 30201763
[TBL] [Abstract][Full Text] [Related]
18. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
19. Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling.
Guo L; Zhou B; Liu Z; Xu Y; Lu H; Xia M; Guo E; Shan W; Chen G; Wang C
Tumour Biol; 2016 Aug; 37(8):11007-15. PubMed ID: 26894601
[TBL] [Abstract][Full Text] [Related]
20. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
Liu T; Li A; Xu Y; Xin Y
Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
